IN8bio, Inc. (NASDAQ:INAB) Short Interest Update

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 433,200 shares, a decline of 51.9% from the January 15th total of 899,800 shares. Approximately 0.8% of the company’s stock are short sold. Based on an average trading volume of 4,110,000 shares, the days-to-cover ratio is currently 0.1 days.

IN8bio Stock Performance

NASDAQ INAB opened at $0.29 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. IN8bio has a 52 week low of $0.22 and a 52 week high of $1.74. The company has a 50 day moving average price of $0.28 and a 200 day moving average price of $0.36.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Equities research analysts predict that IN8bio will post -0.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of IN8bio in a research note on Wednesday.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC increased its stake in IN8bio by 296.7% during the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after purchasing an additional 86,696 shares in the last quarter. Geode Capital Management LLC increased its stake in IN8bio by 56.5% during the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after purchasing an additional 185,919 shares in the last quarter. Sigma Planning Corp increased its stake in IN8bio by 42.0% during the 3rd quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock valued at $230,000 after purchasing an additional 251,600 shares in the last quarter. Franklin Resources Inc. acquired a new position in IN8bio during the 4th quarter valued at approximately $1,465,000. Finally, AIGH Capital Management LLC increased its stake in IN8bio by 269.7% during the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock valued at $1,593,000 after purchasing an additional 4,517,227 shares in the last quarter. Institutional investors and hedge funds own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.